<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907348</url>
  </required_header>
  <id_info>
    <org_study_id>IIL_REAL07</org_study_id>
    <nct_id>NCT00907348</nct_id>
  </id_info>
  <brief_title>Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma</brief_title>
  <acronym>REAL07</acronym>
  <official_title>Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of Treatment With Lenalidomide Plus R-CHOP21 (LR-CHOP21) for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multicenter phase II pilot trial designed with the purpose of dose&#xD;
      finding to evaluate the efficacy and safety of treatment with Lenalidomide plus R-CHOP21&#xD;
      (LR-CHOP21) for elderly patients with untreated Diffuse Large B Cell Lymphoma (DLBCL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of adverse events according with Common Terminology Criteria for Adverse events (CTCAE)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohorts 1 - 2 - 3 - 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LR-CHOP21</intervention_name>
    <description>FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14&#xD;
SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14&#xD;
THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14&#xD;
FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days</description>
    <arm_group_label>Cohorts 1 - 2 - 3 - 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Understand and voluntarily sign an informed consent form&#xD;
&#xD;
          2. Able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
          3. Histologic subtypes as follows:&#xD;
&#xD;
               -  CD20 positive Diffuse large B-Cell lymphoma&#xD;
&#xD;
               -  CD20 positive Follicular grade IIIb&#xD;
&#xD;
          4. Age 60-80&#xD;
&#xD;
          5. Untreated patients. In patients with bulky mass or systemic symptoms or compressive&#xD;
             disease or rapidly progressive adenopathies a pre-study treatment is allowed with&#xD;
             steroids and/or a single dose of Vincristine 1.4 mg/mq (max 2) in the seven days prior&#xD;
             the start of the study treatment&#xD;
&#xD;
          6. Measurable and/or evaluable disease&#xD;
&#xD;
          7. Ann Arbor stage II, III, IV&#xD;
&#xD;
          8. International Prognostic Index at low-intermediate, intermediate-high, high risk&#xD;
             (2/3/4-5)&#xD;
&#xD;
          9. Adequate haematological counts: ANC &gt; 1.5 x 109/L and platelet count &gt; 75 x 109/L&#xD;
             unless due to bone marrow involvement&#xD;
&#xD;
         10. Conjugated bilirubin up to 2 x UNL&#xD;
&#xD;
         11. Alkaline phosphatase and transaminases up to 2 x UNL&#xD;
&#xD;
         12. Creatinine clearance &gt; 50 ml/min&#xD;
&#xD;
         13. HIV negativity&#xD;
&#xD;
         14. HCV negativity&#xD;
&#xD;
         15. HBV negativity or patients with HBVcAb +, HbsAg -, HBs Ab+/- with HBV-DNA negative&#xD;
&#xD;
         16. Cardiac ejection fraction (MUGA scan or echocardiography) &gt; 45%&#xD;
&#xD;
         17. Non peripheral neuropathy or CNS disease. Non testicular Lymphoma&#xD;
&#xD;
         18. Life expectancy &gt; 6 months&#xD;
&#xD;
         19. Performance status &lt; 2 according to ECOG scale&#xD;
&#xD;
         20. Comprehensive geriatric assessment (CGA) as outlined in Appendix 15 showing absence of&#xD;
             any impairment in activity of daily living (ADL), of any condition defining a&#xD;
             geriatric syndrome, and of any grade 4 comorbidity or of more than three grade 3&#xD;
             comorbidities according to CIRS-G scale&#xD;
&#xD;
         21. Disease free of prior malignancies for â‰¥ 3 years with exception of currently treated&#xD;
             basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the cervix&#xD;
             or breast&#xD;
&#xD;
         22. Females of childbearing potential (FCBP) must agree to use two reliable forms of&#xD;
             contraception simultaneously or to practice complete abstinence from heterosexual&#xD;
             intercourse during the following time periods related to this study: for at least 28&#xD;
             days before starting study drug;while participating in the study; for at least 28 days&#xD;
             after discontinuation from the study&#xD;
&#xD;
               -  The two methods of reliable contraception must include one highly effective&#xD;
                  method (i.e., intrauterine device (IUD), hormonal [birth control pills,&#xD;
                  injections, or implants], tubal ligation, partner's vasectomy) and one additional&#xD;
                  effective (barrier) method (i.e., latex condom, diaphragm, cervical cap)&#xD;
&#xD;
               -  FCBP must be referred to a qualified provider of contraceptive methods if needed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lymphoblastic Lymphoma&#xD;
&#xD;
          2. Burkitt Lymphoma&#xD;
&#xD;
          3. Non Hodgkin lymphoma CD 20 negative&#xD;
&#xD;
          4. Mantle Cell Lymphoma&#xD;
&#xD;
          5. Follicular Non Hodgkin Lymphoma grade I-II-IIIa&#xD;
&#xD;
          6. Primitive mediastinal diffuse large B cell lymphoma with only mediastinal involvement&#xD;
&#xD;
          7. International Prognostic Index at low risk (1)&#xD;
&#xD;
          8. Has known or suspected hypersensitivity or intolerance to Rituximab&#xD;
&#xD;
          9. History of evolutive malignancy within the last 3 years other than squamous cell and&#xD;
             basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast&#xD;
&#xD;
         10. Extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy&#xD;
             before enrollment within 3 years before the start of treatment&#xD;
&#xD;
         11. Exposure to Rituximab prior to study entry&#xD;
&#xD;
         12. Have received an experimental drug or used an experimental medical device within 4&#xD;
             weeks before the planned start of treatment. Concurrent participation in non-treatment&#xD;
             studies is allowed, if it will not interfere with participation in this study&#xD;
&#xD;
         13. CNS disease (meningeal and/or brain involvement by lymphoma) or Testicular involvement&#xD;
&#xD;
         14. DVT in the last year&#xD;
&#xD;
         15. History of clinically relevant liver or renal insufficiency; significant cardiac,&#xD;
             vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic,&#xD;
             hematologic, psychiatric, or metabolic disturbances&#xD;
&#xD;
         16. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable&#xD;
             dose for at least 3 months before first dose of study drug&#xD;
&#xD;
         17. Uncontrolled or severe cardiovascular disease including myocardial infarction within 6&#xD;
             months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure&#xD;
             (Attachment 5, NYHA Classification of Cardiac Disease), uncontrolled angina,&#xD;
             clinically significant pericardial disease, or cardiac amyloidosis&#xD;
&#xD;
         18. Creatinine clearance &lt; 50 ml/min&#xD;
&#xD;
         19. Presence of major neurological disorders&#xD;
&#xD;
         20. HIV positivity&#xD;
&#xD;
         21. HBV positivity with the exception of patients with HBVcAb +, HbsAg -, HBs Ab+/- with&#xD;
             HBV-DNA negative&#xD;
&#xD;
         22. HCV positivity&#xD;
&#xD;
         23. Active opportunistic infection&#xD;
&#xD;
         24. Comprehensive geriatric assessment (CGA) as outlined in Appendix 15 showing presence&#xD;
             of any impairment in activity of daily living (ADL), of any condition defining a&#xD;
             geriatric syndrome, and of any grade 4 comorbidity or of more than three grade 3&#xD;
             comorbidities according to CIRS-G scale&#xD;
&#xD;
         25. Any other co-existing medical or psychological condition that would preclude&#xD;
             participation in the study or compromise ability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umberto Vitolo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Azienda Sanitaria Ospedaliera-Universitaria S. Giovanni Battista - TORINO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Divisione di Ematologia Osp. SS. Antonio e Biagio</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Oncologia Medica A Centro di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia UniversitÃ  Policlinico</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Seragnoli&quot; Polic.S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Osp. Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onco-Ematologia I.R.C.C.</name>
      <address>
        <city>Candiolo (TO)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia 1 Ospedale S. Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale Niguarda</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia II FacoltÃ  di Medicina e Chirurgia UniversitÃ  Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia UniversitÃ  Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia UniversitÃ  - Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di biotecnologie cellulari ed ematologia Ospedale Umberto I - La Sapienza</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncoematologia - Univ. Perugia Sede Terni,</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.Ematologia 1 AOU San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia 2 ASO San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia Osp. Cardinale Panico</name>
      <address>
        <city>Tricase (LE)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>May 21, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2009</study_first_posted>
  <last_update_submitted>October 12, 2011</last_update_submitted>
  <last_update_submitted_qc>October 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NHL</keyword>
  <keyword>Non Hodgkin Lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

